NCT03267186View on ClinicalTrials.gov

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Acute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHematopoietic Cell Transplantation Recipient
Interventions
DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

Sponsors

Collaborators (1)

Pharmacyclics LLC.
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

Andrew Rezvani

OTHER

NCT03267186 - Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | Biotech Hunter | Biotech Hunter